Journal
EMBO REPORTS
Volume 5, Issue 10, Pages 1007-1012Publisher
WILEY
DOI: 10.1038/sj.embor.7400254
Keywords
osteoporosis; nuclear receptors; lipodystrophy; extramedullary haematopoiesis
Categories
Funding
- NIDDK NIH HHS [1-P01-DK59820-01, P01 DK059820] Funding Source: Medline
Ask authors/readers for more resources
The peroxisome proliferator-activated receptor gamma (PPARgamma) controls adipogenesis and metabolism. We demonstrate here that the absence of PPARgamma in fat has potent osteogenic activities, which affect haematopoiesis. The congenital absence of PPARgamma in fat of lipodystrophic PPARgamma(hyp/hyp) mice, strongly enhanced bone mass and consequentially reduced the bone-marrow cavity. Consistent with this, PPARgamma(hyp/hyp) mice had a significant decrease in bone marrow cellularity and resorted to extramedullary haematopoiesis in the spleen to maintain haematopoiesis. Our data indicate that antagonizing PPARgamma activity in fat could be an effective way to combat osteoporosis and suggest that haematopoietic function should be scrutinized in lipodystrophic subjects.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available